Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while G&A expenses climbed 41% to $6.9 million due to stock compensation and $1.0 million in pre-commercialization costs. The company ended the quarter with $195 million in cash and marketable securities, providing an anticipated capital runway into 2028.

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Pixabay/Public domain

The company is preparing for a BLA submission and an FDA meeting later this year for tovecimig, which recently received Orphan Drug Designation for biliary tract cancer/BTC. In a Phase 2/3 study, the tovecimig combination met its primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone. It also significantly improved median progression-free survival to 4.7 months compared to 2.6 months for the control group.

Compass Therapeutics Inc. (NASDAQ:CMPX) has also initiated cohort expansions for CTX-8371 across breast, lung, and lymphoma indications, with initial data scheduled for presentation at ASCO 2026. Additionally, a Phase 1 study has commenced for CTX-10726 in solid tumors, with initial data expected in Q4 2026. Finally, a Phase 2 trial for the company’s CD137 agonist, CTX-471, is on track to begin in H2 2026.

Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics for the treatment of various human diseases in the US.

While we acknowledge the risk and potential of CMPX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1